• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GLP-1 受体激动剂治疗患者的胆石症：随机对照试验的更新荟萃分析。

Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.

机构信息

Diabetology, Careggi Hospital and University of Florence, Italy.

Diabetology, Careggi Hospital and University of Florence, Italy.

出版信息

Diabetes Res Clin Pract. 2020 Mar;161:108087. doi: 10.1016/j.diabres.2020.108087. Epub 2020 Feb 19.

DOI:10.1016/j.diabres.2020.108087
PMID:32084455
Abstract

Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) has been associated with cholelithiasis in a previous meta-analysis. The publication of new trials suggests the need for an update. We collected trials with GLP1-RA vs. other therapies, calculating Mantel-Haenszel odds ratio (MH-OR, 95%CI). GLP1-RA significantly increased the risk of cholelithiasis (MH-OR 1.28 [1.11, 1.48]).

摘要

胰高血糖素样肽-1 受体激动剂 (GLP1-RA) 在前一次荟萃分析中与胆石症相关。新试验的发表表明需要更新。我们收集了 GLP1-RA 与其他疗法的试验，计算了 Mantel-Haenszel 优势比 (MH-OR，95%CI)。GLP1-RA 显著增加了胆石症的风险 (MH-OR 1.28 [1.11, 1.48])。

相似文献

1
Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.GLP-1 受体激动剂治疗患者的胆石症：随机对照试验的更新荟萃分析。
Diabetes Res Clin Pract. 2020 Mar;161:108087. doi: 10.1016/j.diabres.2020.108087. Epub 2020 Feb 19.
2
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.胰高血糖素样肽-1 受体激动剂（胰腺炎、胰腺癌和胆石症）的安全性问题：来自随机对照试验的数据。
Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926. Epub 2017 Jun 20.
3
Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂在 2 型糖尿病中的微血管作用：一项随机对照试验的荟萃分析。
Acta Diabetol. 2017 Oct;54(10):933-941. doi: 10.1007/s00592-017-1031-9. Epub 2017 Jul 27.
4
Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.接受胰高血糖素样肽-1 受体激动剂治疗的患者的主要心血管事件、心力衰竭和心房颤动：随机对照试验的更新荟萃分析。
Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1106-1114. doi: 10.1016/j.numecd.2020.03.013. Epub 2020 Mar 25.
5
Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.胰高血糖素样肽-1受体激动剂治疗的2型糖尿病患者的胰腺炎和胰腺癌：随机对照试验的最新荟萃分析
Minerva Endocrinol (Torino). 2023 Jun;48(2):206-213. doi: 10.23736/S2724-6507.20.03219-8. Epub 2020 Jul 23.
6
Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.胰高血糖素样肽-1 受体激动剂与有或无心血管事件史患者的心血管结局：随机对照试验的更新荟萃分析和亚组分析。
Diabetes Obes Metab. 2020 Feb;22(2):203-211. doi: 10.1111/dom.13888. Epub 2019 Oct 24.
7
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).2 型糖尿病伴非酒精性脂肪性肝病的胰高血糖素样肽 1 受体激动剂（GLP1-RA）作用的荟萃分析。
Sci Rep. 2021 Nov 11;11(1):22063. doi: 10.1038/s41598-021-01663-y.
8
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的心力衰竭：随机和观察性研究的系统评价与荟萃分析
BMC Cardiovasc Disord. 2016 May 11;16:91. doi: 10.1186/s12872-016-0260-0.
9
Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.胰高血糖素样肽-1 受体激动剂与胰腺炎：随机临床试验的荟萃分析。
Diabetes Res Clin Pract. 2014 Feb;103(2):269-75. doi: 10.1016/j.diabres.2014.01.010. Epub 2014 Jan 14.
10
Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.胰高血糖素样肽 1 受体激动剂在伴有或不伴有慢性心力衰竭的 2 型糖尿病患者中的应用：一项随机安慰剂对照结局试验的荟萃分析。
Diabetes Obes Metab. 2023 Jun;25(6):1495-1502. doi: 10.1111/dom.14997. Epub 2023 Feb 20.

引用本文的文献

1
Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database.胰高血糖素样肽-1受体激动剂诱发的胆囊炎和胆石症：一项使用FAERS数据库的真实世界药物警戒分析
Front Pharmacol. 2025 Jul 8;16:1557691. doi: 10.3389/fphar.2025.1557691. eCollection 2025.
2
Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis.胰高血糖素样肽-1受体激动剂与二肽基肽酶-4抑制剂和胆道疾病之间的关联：药物警戒分析
Front Pharmacol. 2025 Feb 17;16:1509561. doi: 10.3389/fphar.2025.1509561. eCollection 2025.
3
The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.
2型糖尿病患者中胰高血糖素样肽-1受体激动剂相关临床显著胆石症的相对风险：一项真实世界研究
Diabetol Metab Syndr. 2024 Dec 4;16(1):293. doi: 10.1186/s13098-024-01526-2.
4
Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system.2型糖尿病患者中基于肠促胰岛素的治疗与肝胆疾病的关联：来自美国食品药品监督管理局不良事件报告系统的病例系列
Endocr Connect. 2024 Nov 25;13(12). doi: 10.1530/EC-24-0404. Print 2024 Dec 1.
5
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations.临床洞察：司美格鲁肽用于成人慢性体重管理：患者选择和特殊考虑。
Drug Des Devel Ther. 2022 Dec 29;16:4449-4461. doi: 10.2147/DDDT.S365416. eCollection 2022.
6
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.二肽基肽酶-4 抑制剂与 2 型糖尿病患者的胆囊或胆道疾病：系统评价及随机对照试验的两两和网络荟萃分析。
BMJ. 2022 Jun 28;377:e068882. doi: 10.1136/bmj-2021-068882.
7
Semaglutide for the treatment of obesity.司美格鲁肽用于治疗肥胖症。
Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21.
8
Safety of Semaglutide.司美格鲁肽的安全性。
Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.
9
A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.利拉鲁肽在“糖尿病肥胖症”现代治疗中的应用2021年更新：一篇叙述性综述
Medicina (Kaunas). 2021 Jun 29;57(7):669. doi: 10.3390/medicina57070669.
10
Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes.利拉鲁肽治疗肥胖症及糖尿病的相关副作用。
J Obes Metab Syndr. 2021 Mar 30;30(1):12-19. doi: 10.7570/jomes20059.